Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some claims are consistent with the provided COSENTYX labeling excerpts (IL-17A antagonist, increased infection risk, avoiding live vaccines), but multiple MMR-vaccine-specific assertions are not supported by the provided label text, and several statements add details (immune suppression causing reduced vaccine effectiveness, specific adverse reaction types/risks, blood-test/immune response monitoring, and timing) that are not found in the supplied excerpts.
Category Scores
Accurate Statements
Cosentyx (secukinumab) blocks the action of interleukin-17A (IL-17A).
COSENTYX excerpt provided: "Active ingredient: secukinumab (IL-17A antagonist)" and 12.2/12.3 context does not contradict; label excerpt characterizes IL-17 inhibitors including COSENTYX.
Cosentyx may increase the risk of infections, including viral infections.
5.1 Infections: "COSENTYX may increase the risk of infections" and "serious bacterial, viral, and fungal opportunistic infections..."
Cosentyx may alter a patient's immune response to live vaccines; avoid use of live vaccines in patients treated with Cosentyx.
5.7 Immunizations: "COSENTYX may alter a patient's immune response to live vaccines. Avoid use of live vaccines"; 12.2 also states this.
Unsupported Statements
Cosentyx is used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis.
No indication text for psoriasis/psoriatic arthritis/ankylosing spondylitis was included in the provided label excerpts.
The MMR vaccine is a live, attenuated vaccine.
MMR vaccine properties are not addressed in the provided COSENTYX label excerpts.
There is no specific contraindication for taking Cosentyx with the MMR vaccine according to Cosentyx prescribing information.
The provided excerpts list contraindications only for prior serious hypersensitivity; they do not address MMR specifically (live vaccine avoidance is a warning/precaution, not a contraindication in the provided text).
There is no evidence suggesting Cosentyx would interfere with the MMR vaccine.
The provided excerpts state COSENTYX may alter immune response to live vaccines and advises avoiding live vaccines; this conflicts with the 'no evidence' assertion.
Cosentyx may reduce the effectiveness of the MMR vaccine because it suppresses the immune system.
The provided excerpts do not mention MMR effectiveness or specifically say 'reduces effectiveness'; they state immune response to live vaccines may be altered (immunosuppression language is not used in the provided excerpts).
When taking Cosentyx with the MMR vaccine, there is a small risk of adverse reactions such as fever, rash, or injection-site reactions.
The provided excerpts do not list MMR-specific adverse reaction types or quantify 'small risk' for concurrent administration.
A healthcare provider may recommend a blood test to check immune response to the MMR vaccine in patients taking Cosentyx.
The provided excerpts do not recommend any blood-test/immune-response monitoring related to MMR vaccination.
A healthcare provider may recommend delaying the MMR vaccine until Cosentyx treatment is complete in some situations.
The provided excerpts recommend considering completion of age-appropriate immunizations prior to initiating COSENTYX and avoiding live vaccines, but do not provide specific guidance to delay MMR until treatment is complete.
Contradictions
Low
AI Statement
There is no evidence suggesting Cosentyx would interfere with the MMR vaccine.
Label Reference
5.7 Immunizations: "COSENTYX may alter a patient's immune response to live vaccines. Avoid use of live vaccines in patients treated with COSENTYX."
Important Omissions
For any MMR/vaccine-related claim, the provided label excerpts support avoiding live vaccines and considering immunizations prior to initiating COSENTYX, but the AI response does not ground vaccine-related statements in these label instructions (e.g., it instead asserts 'no evidence' and provides MMR-specific delay/testing details not present).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
MMR-specific assertions (no interference/effectiveness reduction/injection-site fever/rash risk, blood testing, and delaying until completion) are not supported by the supplied label excerpts and could mislead about live-vaccine guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple MMR-specific statements are not supported by the provided COSENTYX label excerpts and include at least one claim directly inconsistent with the label's live-vaccine caution.
Suggested Improvement
Limit vaccine-related content to what the provided label supports: consider completion of age-appropriate immunizations prior to initiating COSENTYX and avoid use of live vaccines; remove 'no evidence' and MMR-specific effectiveness/adverse reaction/blood test/delay-to-completion assertions unless present in the supplied label text.